Encephalitis, Japanese B Completed Phase 4 Trials for Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (DB10769)

Also known as: Japanese Encephalitis / Encephalitis Japanese B / Encephalitis, Japanese / Japanese B encephalitis / Japanese B viral encephalitis

IndicationStatusPhase
DBCOND0033957 (Encephalitis, Japanese B)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01158599This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly PopulationPrevention
NCT01656200A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2Basic Science
NCT02532569Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis VaccineinjPrevention
NCT02880865Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) VaccinePrevention